nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—ABCB1—Vismodegib—skin cancer	0.0938	0.142	CbGbCtD
Nefazodone—CYP3A4—Imiquimod—skin cancer	0.081	0.123	CbGbCtD
Nefazodone—CYP3A4—Temozolomide—skin cancer	0.081	0.123	CbGbCtD
Nefazodone—CYP2D6—Vemurafenib—skin cancer	0.0698	0.106	CbGbCtD
Nefazodone—CYP3A4—Vismodegib—skin cancer	0.0562	0.0852	CbGbCtD
Nefazodone—CYP3A7—Docetaxel—skin cancer	0.0521	0.079	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Docetaxel—skin cancer	0.0521	0.079	CbGbCtD
Nefazodone—ABCB1—Dactinomycin—skin cancer	0.0492	0.0747	CbGbCtD
Nefazodone—CYP3A4—Vemurafenib—skin cancer	0.0444	0.0673	CbGbCtD
Nefazodone—CYP3A5—Docetaxel—skin cancer	0.0391	0.0593	CbGbCtD
Nefazodone—ABCB1—Docetaxel—skin cancer	0.0254	0.0386	CbGbCtD
Nefazodone—CYP3A4—Docetaxel—skin cancer	0.0152	0.0231	CbGbCtD
Nefazodone—SLC6A3—nerve—skin cancer	0.000919	0.0933	CbGeAlD
Nefazodone—SLC6A2—nerve—skin cancer	0.000742	0.0753	CbGeAlD
Nefazodone—HTR2A—hindlimb—skin cancer	0.000733	0.0744	CbGeAlD
Nefazodone—HTR2A—appendage—skin cancer	0.000629	0.0638	CbGeAlD
Nefazodone—Visual impairment—Temozolomide—skin cancer	0.000539	0.00163	CcSEcCtD
Nefazodone—Sinusitis—Fluorouracil—skin cancer	0.000539	0.00163	CcSEcCtD
Nefazodone—Gastrointestinal haemorrhage—Docetaxel—skin cancer	0.000538	0.00163	CcSEcCtD
Nefazodone—Ill-defined disorder—Bleomycin—skin cancer	0.000536	0.00162	CcSEcCtD
Nefazodone—Anaemia—Bleomycin—skin cancer	0.000534	0.00161	CcSEcCtD
Nefazodone—Diarrhoea—Vemurafenib—skin cancer	0.000532	0.00161	CcSEcCtD
Nefazodone—Migraine—Docetaxel—skin cancer	0.000529	0.0016	CcSEcCtD
Nefazodone—Erythema multiforme—Temozolomide—skin cancer	0.000529	0.0016	CcSEcCtD
Nefazodone—Urticaria—Imiquimod—skin cancer	0.000527	0.00159	CcSEcCtD
Nefazodone—Abdominal pain—Imiquimod—skin cancer	0.000524	0.00159	CcSEcCtD
Nefazodone—Body temperature increased—Imiquimod—skin cancer	0.000524	0.00159	CcSEcCtD
Nefazodone—Tinnitus—Temozolomide—skin cancer	0.000522	0.00158	CcSEcCtD
Nefazodone—Malaise—Bleomycin—skin cancer	0.000521	0.00157	CcSEcCtD
Nefazodone—Flushing—Temozolomide—skin cancer	0.000519	0.00157	CcSEcCtD
Nefazodone—Haemoglobin—Fluorouracil—skin cancer	0.000518	0.00157	CcSEcCtD
Nefazodone—Leukopenia—Bleomycin—skin cancer	0.000517	0.00156	CcSEcCtD
Nefazodone—Rhinitis—Fluorouracil—skin cancer	0.000517	0.00156	CcSEcCtD
Nefazodone—Haemorrhage—Fluorouracil—skin cancer	0.000516	0.00156	CcSEcCtD
Nefazodone—Dizziness—Vemurafenib—skin cancer	0.000514	0.00156	CcSEcCtD
Nefazodone—Hypoaesthesia—Fluorouracil—skin cancer	0.000513	0.00155	CcSEcCtD
Nefazodone—Pharyngitis—Fluorouracil—skin cancer	0.000512	0.00155	CcSEcCtD
Nefazodone—Ataxia—Docetaxel—skin cancer	0.000506	0.00153	CcSEcCtD
Nefazodone—Cough—Bleomycin—skin cancer	0.000504	0.00152	CcSEcCtD
Nefazodone—Chills—Temozolomide—skin cancer	0.000502	0.00152	CcSEcCtD
Nefazodone—Dehydration—Docetaxel—skin cancer	0.0005	0.00151	CcSEcCtD
Nefazodone—Ill-defined disorder—Dactinomycin—skin cancer	0.0005	0.00151	CcSEcCtD
Nefazodone—Anaemia—Dactinomycin—skin cancer	0.000498	0.0015	CcSEcCtD
Nefazodone—Liver function test abnormal—Docetaxel—skin cancer	0.000497	0.0015	CcSEcCtD
Nefazodone—Vomiting—Vemurafenib—skin cancer	0.000495	0.0015	CcSEcCtD
Nefazodone—Alopecia—Temozolomide—skin cancer	0.000494	0.00149	CcSEcCtD
Nefazodone—Dry skin—Docetaxel—skin cancer	0.000493	0.00149	CcSEcCtD
Nefazodone—Chest pain—Bleomycin—skin cancer	0.000492	0.00149	CcSEcCtD
Nefazodone—Myalgia—Bleomycin—skin cancer	0.000492	0.00149	CcSEcCtD
Nefazodone—Orthostatic hypotension—Docetaxel—skin cancer	0.000491	0.00149	CcSEcCtD
Nefazodone—Rash—Vemurafenib—skin cancer	0.00049	0.00148	CcSEcCtD
Nefazodone—Dermatitis—Vemurafenib—skin cancer	0.00049	0.00148	CcSEcCtD
Nefazodone—Hypersensitivity—Imiquimod—skin cancer	0.000489	0.00148	CcSEcCtD
Nefazodone—Headache—Vemurafenib—skin cancer	0.000487	0.00147	CcSEcCtD
Nefazodone—Discomfort—Bleomycin—skin cancer	0.000486	0.00147	CcSEcCtD
Nefazodone—Malaise—Dactinomycin—skin cancer	0.000486	0.00147	CcSEcCtD
Nefazodone—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000484	0.00146	CcSEcCtD
Nefazodone—Cramp muscle—Docetaxel—skin cancer	0.000484	0.00146	CcSEcCtD
Nefazodone—Leukopenia—Dactinomycin—skin cancer	0.000482	0.00146	CcSEcCtD
Nefazodone—Dysgeusia—Temozolomide—skin cancer	0.000477	0.00144	CcSEcCtD
Nefazodone—Asthenia—Imiquimod—skin cancer	0.000476	0.00144	CcSEcCtD
Nefazodone—Confusional state—Bleomycin—skin cancer	0.000475	0.00144	CcSEcCtD
Nefazodone—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000474	0.00143	CcSEcCtD
Nefazodone—Oedema—Bleomycin—skin cancer	0.000471	0.00142	CcSEcCtD
Nefazodone—Anaphylactic shock—Bleomycin—skin cancer	0.000471	0.00142	CcSEcCtD
Nefazodone—Back pain—Temozolomide—skin cancer	0.000471	0.00142	CcSEcCtD
Nefazodone—Pruritus—Imiquimod—skin cancer	0.000469	0.00142	CcSEcCtD
Nefazodone—Infection—Bleomycin—skin cancer	0.000468	0.00142	CcSEcCtD
Nefazodone—Dysphagia—Docetaxel—skin cancer	0.000465	0.00141	CcSEcCtD
Nefazodone—Nausea—Vemurafenib—skin cancer	0.000462	0.0014	CcSEcCtD
Nefazodone—Thrombocytopenia—Bleomycin—skin cancer	0.000461	0.00139	CcSEcCtD
Nefazodone—Vision blurred—Temozolomide—skin cancer	0.000459	0.00139	CcSEcCtD
Nefazodone—Myalgia—Dactinomycin—skin cancer	0.000458	0.00139	CcSEcCtD
Nefazodone—Tremor—Temozolomide—skin cancer	0.000456	0.00138	CcSEcCtD
Nefazodone—Alopecia—Fluorouracil—skin cancer	0.000456	0.00138	CcSEcCtD
Nefazodone—Diarrhoea—Imiquimod—skin cancer	0.000454	0.00137	CcSEcCtD
Nefazodone—Discomfort—Dactinomycin—skin cancer	0.000453	0.00137	CcSEcCtD
Nefazodone—Angina pectoris—Docetaxel—skin cancer	0.000453	0.00137	CcSEcCtD
Nefazodone—Ill-defined disorder—Temozolomide—skin cancer	0.000452	0.00137	CcSEcCtD
Nefazodone—Anaemia—Temozolomide—skin cancer	0.00045	0.00136	CcSEcCtD
Nefazodone—Anorexia—Bleomycin—skin cancer	0.000449	0.00136	CcSEcCtD
Nefazodone—Agitation—Temozolomide—skin cancer	0.000448	0.00135	CcSEcCtD
Nefazodone—HTR2A—nerve—skin cancer	0.000446	0.0452	CbGeAlD
Nefazodone—Angioedema—Temozolomide—skin cancer	0.000445	0.00135	CcSEcCtD
Nefazodone—Hypotension—Bleomycin—skin cancer	0.00044	0.00133	CcSEcCtD
Nefazodone—Oedema—Dactinomycin—skin cancer	0.000439	0.00133	CcSEcCtD
Nefazodone—Malaise—Temozolomide—skin cancer	0.000439	0.00133	CcSEcCtD
Nefazodone—Dizziness—Imiquimod—skin cancer	0.000439	0.00133	CcSEcCtD
Nefazodone—Vertigo—Temozolomide—skin cancer	0.000438	0.00132	CcSEcCtD
Nefazodone—Infection—Dactinomycin—skin cancer	0.000437	0.00132	CcSEcCtD
Nefazodone—Leukopenia—Temozolomide—skin cancer	0.000436	0.00132	CcSEcCtD
Nefazodone—Palpitations—Temozolomide—skin cancer	0.00043	0.0013	CcSEcCtD
Nefazodone—Thrombocytopenia—Dactinomycin—skin cancer	0.00043	0.0013	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000429	0.0013	CcSEcCtD
Nefazodone—Cough—Temozolomide—skin cancer	0.000425	0.00129	CcSEcCtD
Nefazodone—Paraesthesia—Bleomycin—skin cancer	0.000423	0.00128	CcSEcCtD
Nefazodone—Weight increased—Docetaxel—skin cancer	0.000423	0.00128	CcSEcCtD
Nefazodone—Vision blurred—Fluorouracil—skin cancer	0.000423	0.00128	CcSEcCtD
Nefazodone—Convulsion—Temozolomide—skin cancer	0.000422	0.00128	CcSEcCtD
Nefazodone—Vomiting—Imiquimod—skin cancer	0.000422	0.00128	CcSEcCtD
Nefazodone—Weight decreased—Docetaxel—skin cancer	0.000421	0.00127	CcSEcCtD
Nefazodone—Hypertension—Temozolomide—skin cancer	0.000421	0.00127	CcSEcCtD
Nefazodone—Dyspnoea—Bleomycin—skin cancer	0.00042	0.00127	CcSEcCtD
Nefazodone—Anorexia—Dactinomycin—skin cancer	0.000419	0.00127	CcSEcCtD
Nefazodone—Rash—Imiquimod—skin cancer	0.000418	0.00126	CcSEcCtD
Nefazodone—Dermatitis—Imiquimod—skin cancer	0.000418	0.00126	CcSEcCtD
Nefazodone—Pneumonia—Docetaxel—skin cancer	0.000417	0.00126	CcSEcCtD
Nefazodone—Headache—Imiquimod—skin cancer	0.000416	0.00126	CcSEcCtD
Nefazodone—Anaemia—Fluorouracil—skin cancer	0.000415	0.00125	CcSEcCtD
Nefazodone—Myalgia—Temozolomide—skin cancer	0.000415	0.00125	CcSEcCtD
Nefazodone—Arthralgia—Temozolomide—skin cancer	0.000415	0.00125	CcSEcCtD
Nefazodone—Anxiety—Temozolomide—skin cancer	0.000413	0.00125	CcSEcCtD
Nefazodone—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000411	0.00124	CcSEcCtD
Nefazodone—Discomfort—Temozolomide—skin cancer	0.00041	0.00124	CcSEcCtD
Nefazodone—Decreased appetite—Bleomycin—skin cancer	0.00041	0.00124	CcSEcCtD
Nefazodone—Dry mouth—Temozolomide—skin cancer	0.000406	0.00123	CcSEcCtD
Nefazodone—Stomatitis—Docetaxel—skin cancer	0.000404	0.00122	CcSEcCtD
Nefazodone—Pain—Bleomycin—skin cancer	0.000403	0.00122	CcSEcCtD
Nefazodone—Conjunctivitis—Docetaxel—skin cancer	0.000403	0.00122	CcSEcCtD
Nefazodone—Leukopenia—Fluorouracil—skin cancer	0.000402	0.00121	CcSEcCtD
Nefazodone—Confusional state—Temozolomide—skin cancer	0.000401	0.00121	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.0004	0.00121	CcSEcCtD
Nefazodone—Oedema—Temozolomide—skin cancer	0.000398	0.0012	CcSEcCtD
Nefazodone—Anaphylactic shock—Temozolomide—skin cancer	0.000398	0.0012	CcSEcCtD
Nefazodone—Infection—Temozolomide—skin cancer	0.000395	0.00119	CcSEcCtD
Nefazodone—Nausea—Imiquimod—skin cancer	0.000394	0.00119	CcSEcCtD
Nefazodone—Epistaxis—Docetaxel—skin cancer	0.000391	0.00118	CcSEcCtD
Nefazodone—Thrombocytopenia—Temozolomide—skin cancer	0.000389	0.00118	CcSEcCtD
Nefazodone—Convulsion—Fluorouracil—skin cancer	0.000389	0.00118	CcSEcCtD
Nefazodone—Feeling abnormal—Bleomycin—skin cancer	0.000388	0.00117	CcSEcCtD
Nefazodone—Hyperhidrosis—Temozolomide—skin cancer	0.000384	0.00116	CcSEcCtD
Nefazodone—Chest pain—Fluorouracil—skin cancer	0.000382	0.00116	CcSEcCtD
Nefazodone—Myalgia—Fluorouracil—skin cancer	0.000382	0.00116	CcSEcCtD
Nefazodone—Decreased appetite—Dactinomycin—skin cancer	0.000382	0.00116	CcSEcCtD
Nefazodone—HTR2A—endothelium—skin cancer	0.00038	0.0385	CbGeAlD
Nefazodone—Anorexia—Temozolomide—skin cancer	0.000379	0.00115	CcSEcCtD
Nefazodone—Discomfort—Fluorouracil—skin cancer	0.000377	0.00114	CcSEcCtD
Nefazodone—Pain—Dactinomycin—skin cancer	0.000376	0.00114	CcSEcCtD
Nefazodone—Urticaria—Bleomycin—skin cancer	0.000374	0.00113	CcSEcCtD
Nefazodone—Haemoglobin—Docetaxel—skin cancer	0.000374	0.00113	CcSEcCtD
Nefazodone—Rhinitis—Docetaxel—skin cancer	0.000373	0.00113	CcSEcCtD
Nefazodone—Body temperature increased—Bleomycin—skin cancer	0.000373	0.00113	CcSEcCtD
Nefazodone—Haemorrhage—Docetaxel—skin cancer	0.000372	0.00112	CcSEcCtD
Nefazodone—Hepatitis—Docetaxel—skin cancer	0.000372	0.00112	CcSEcCtD
Nefazodone—Hypoaesthesia—Docetaxel—skin cancer	0.00037	0.00112	CcSEcCtD
Nefazodone—Confusional state—Fluorouracil—skin cancer	0.000369	0.00112	CcSEcCtD
Nefazodone—Pharyngitis—Docetaxel—skin cancer	0.000369	0.00112	CcSEcCtD
Nefazodone—Oedema peripheral—Docetaxel—skin cancer	0.000367	0.00111	CcSEcCtD
Nefazodone—Oedema—Fluorouracil—skin cancer	0.000366	0.00111	CcSEcCtD
Nefazodone—Anaphylactic shock—Fluorouracil—skin cancer	0.000366	0.00111	CcSEcCtD
Nefazodone—Infection—Fluorouracil—skin cancer	0.000364	0.0011	CcSEcCtD
Nefazodone—Feeling abnormal—Dactinomycin—skin cancer	0.000362	0.00109	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000362	0.00109	CcSEcCtD
Nefazodone—Insomnia—Temozolomide—skin cancer	0.00036	0.00109	CcSEcCtD
Nefazodone—Gastrointestinal pain—Dactinomycin—skin cancer	0.000359	0.00109	CcSEcCtD
Nefazodone—Thrombocytopenia—Fluorouracil—skin cancer	0.000359	0.00108	CcSEcCtD
Nefazodone—Visual impairment—Docetaxel—skin cancer	0.000359	0.00108	CcSEcCtD
Nefazodone—Tachycardia—Fluorouracil—skin cancer	0.000357	0.00108	CcSEcCtD
Nefazodone—Paraesthesia—Temozolomide—skin cancer	0.000357	0.00108	CcSEcCtD
Nefazodone—Dyspnoea—Temozolomide—skin cancer	0.000354	0.00107	CcSEcCtD
Nefazodone—Somnolence—Temozolomide—skin cancer	0.000353	0.00107	CcSEcCtD
Nefazodone—Erythema multiforme—Docetaxel—skin cancer	0.000352	0.00106	CcSEcCtD
Nefazodone—HTR2A—blood vessel—skin cancer	0.00035	0.0355	CbGeAlD
Nefazodone—Dyspepsia—Temozolomide—skin cancer	0.00035	0.00106	CcSEcCtD
Nefazodone—Anorexia—Fluorouracil—skin cancer	0.000349	0.00106	CcSEcCtD
Nefazodone—Abdominal pain—Dactinomycin—skin cancer	0.000347	0.00105	CcSEcCtD
Nefazodone—Body temperature increased—Dactinomycin—skin cancer	0.000347	0.00105	CcSEcCtD
Nefazodone—Hypersensitivity—Bleomycin—skin cancer	0.000347	0.00105	CcSEcCtD
Nefazodone—Decreased appetite—Temozolomide—skin cancer	0.000346	0.00104	CcSEcCtD
Nefazodone—Flushing—Docetaxel—skin cancer	0.000345	0.00104	CcSEcCtD
Nefazodone—Hypotension—Fluorouracil—skin cancer	0.000342	0.00103	CcSEcCtD
Nefazodone—Pain—Temozolomide—skin cancer	0.00034	0.00103	CcSEcCtD
Nefazodone—Constipation—Temozolomide—skin cancer	0.00034	0.00103	CcSEcCtD
Nefazodone—Asthenia—Bleomycin—skin cancer	0.000338	0.00102	CcSEcCtD
Nefazodone—Chills—Docetaxel—skin cancer	0.000334	0.00101	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000334	0.00101	CcSEcCtD
Nefazodone—Pruritus—Bleomycin—skin cancer	0.000333	0.00101	CcSEcCtD
Nefazodone—Insomnia—Fluorouracil—skin cancer	0.000331	0.001	CcSEcCtD
Nefazodone—Paraesthesia—Fluorouracil—skin cancer	0.000329	0.000994	CcSEcCtD
Nefazodone—Alopecia—Docetaxel—skin cancer	0.000329	0.000994	CcSEcCtD
Nefazodone—Feeling abnormal—Temozolomide—skin cancer	0.000328	0.00099	CcSEcCtD
Nefazodone—Dyspnoea—Fluorouracil—skin cancer	0.000327	0.000987	CcSEcCtD
Nefazodone—Somnolence—Fluorouracil—skin cancer	0.000326	0.000984	CcSEcCtD
Nefazodone—Gastrointestinal pain—Temozolomide—skin cancer	0.000325	0.000983	CcSEcCtD
Nefazodone—Hypersensitivity—Dactinomycin—skin cancer	0.000324	0.000979	CcSEcCtD
Nefazodone—Dyspepsia—Fluorouracil—skin cancer	0.000322	0.000975	CcSEcCtD
Nefazodone—Decreased appetite—Fluorouracil—skin cancer	0.000318	0.000963	CcSEcCtD
Nefazodone—Dysgeusia—Docetaxel—skin cancer	0.000317	0.000959	CcSEcCtD
Nefazodone—Urticaria—Temozolomide—skin cancer	0.000316	0.000955	CcSEcCtD
Nefazodone—Asthenia—Dactinomycin—skin cancer	0.000315	0.000953	CcSEcCtD
Nefazodone—Abdominal pain—Temozolomide—skin cancer	0.000314	0.00095	CcSEcCtD
Nefazodone—Body temperature increased—Temozolomide—skin cancer	0.000314	0.00095	CcSEcCtD
Nefazodone—Back pain—Docetaxel—skin cancer	0.000313	0.000947	CcSEcCtD
Nefazodone—Pain—Fluorouracil—skin cancer	0.000313	0.000947	CcSEcCtD
Nefazodone—Muscle spasms—Docetaxel—skin cancer	0.000311	0.000942	CcSEcCtD
Nefazodone—Feeling abnormal—Fluorouracil—skin cancer	0.000302	0.000913	CcSEcCtD
Nefazodone—Diarrhoea—Dactinomycin—skin cancer	0.000301	0.000909	CcSEcCtD
Nefazodone—Vomiting—Bleomycin—skin cancer	0.0003	0.000906	CcSEcCtD
Nefazodone—Anaemia—Docetaxel—skin cancer	0.000299	0.000905	CcSEcCtD
Nefazodone—ADRA2A—nipple—skin cancer	0.000298	0.0302	CbGeAlD
Nefazodone—Rash—Bleomycin—skin cancer	0.000297	0.000898	CcSEcCtD
Nefazodone—Dermatitis—Bleomycin—skin cancer	0.000297	0.000898	CcSEcCtD
Nefazodone—Hypersensitivity—Temozolomide—skin cancer	0.000293	0.000885	CcSEcCtD
Nefazodone—ADRA1B—head—skin cancer	0.000291	0.0295	CbGeAlD
Nefazodone—Urticaria—Fluorouracil—skin cancer	0.000291	0.00088	CcSEcCtD
Nefazodone—Syncope—Docetaxel—skin cancer	0.00029	0.000878	CcSEcCtD
Nefazodone—Leukopenia—Docetaxel—skin cancer	0.00029	0.000877	CcSEcCtD
Nefazodone—Body temperature increased—Fluorouracil—skin cancer	0.00029	0.000875	CcSEcCtD
Nefazodone—Palpitations—Docetaxel—skin cancer	0.000286	0.000865	CcSEcCtD
Nefazodone—Asthenia—Temozolomide—skin cancer	0.000285	0.000862	CcSEcCtD
Nefazodone—Loss of consciousness—Docetaxel—skin cancer	0.000285	0.000861	CcSEcCtD
Nefazodone—Cough—Docetaxel—skin cancer	0.000283	0.000855	CcSEcCtD
Nefazodone—Pruritus—Temozolomide—skin cancer	0.000281	0.00085	CcSEcCtD
Nefazodone—Convulsion—Docetaxel—skin cancer	0.000281	0.000848	CcSEcCtD
Nefazodone—Nausea—Bleomycin—skin cancer	0.00028	0.000846	CcSEcCtD
Nefazodone—Hypertension—Docetaxel—skin cancer	0.00028	0.000845	CcSEcCtD
Nefazodone—Vomiting—Dactinomycin—skin cancer	0.000279	0.000845	CcSEcCtD
Nefazodone—Rash—Dactinomycin—skin cancer	0.000277	0.000838	CcSEcCtD
Nefazodone—Chest pain—Docetaxel—skin cancer	0.000276	0.000834	CcSEcCtD
Nefazodone—Myalgia—Docetaxel—skin cancer	0.000276	0.000834	CcSEcCtD
Nefazodone—Arthralgia—Docetaxel—skin cancer	0.000276	0.000834	CcSEcCtD
Nefazodone—Diarrhoea—Temozolomide—skin cancer	0.000272	0.000822	CcSEcCtD
Nefazodone—Hypersensitivity—Fluorouracil—skin cancer	0.00027	0.000816	CcSEcCtD
Nefazodone—Dry mouth—Docetaxel—skin cancer	0.00027	0.000815	CcSEcCtD
Nefazodone—Confusional state—Docetaxel—skin cancer	0.000267	0.000806	CcSEcCtD
Nefazodone—Oedema—Docetaxel—skin cancer	0.000264	0.000799	CcSEcCtD
Nefazodone—Anaphylactic shock—Docetaxel—skin cancer	0.000264	0.000799	CcSEcCtD
Nefazodone—ADRA1A—epithelium—skin cancer	0.000264	0.0267	CbGeAlD
Nefazodone—Dizziness—Temozolomide—skin cancer	0.000263	0.000795	CcSEcCtD
Nefazodone—Infection—Docetaxel—skin cancer	0.000263	0.000794	CcSEcCtD
Nefazodone—Nausea—Dactinomycin—skin cancer	0.000261	0.000789	CcSEcCtD
Nefazodone—Shock—Docetaxel—skin cancer	0.00026	0.000786	CcSEcCtD
Nefazodone—Pruritus—Fluorouracil—skin cancer	0.000259	0.000783	CcSEcCtD
Nefazodone—Thrombocytopenia—Docetaxel—skin cancer	0.000259	0.000783	CcSEcCtD
Nefazodone—Tachycardia—Docetaxel—skin cancer	0.000258	0.00078	CcSEcCtD
Nefazodone—Vomiting—Temozolomide—skin cancer	0.000253	0.000764	CcSEcCtD
Nefazodone—HTR2C—female reproductive system—skin cancer	0.000252	0.0256	CbGeAlD
Nefazodone—Anorexia—Docetaxel—skin cancer	0.000252	0.000762	CcSEcCtD
Nefazodone—Rash—Temozolomide—skin cancer	0.000251	0.000758	CcSEcCtD
Nefazodone—Diarrhoea—Fluorouracil—skin cancer	0.000251	0.000758	CcSEcCtD
Nefazodone—HTR2A—neck—skin cancer	0.00025	0.0254	CbGeAlD
Nefazodone—Dermatitis—Temozolomide—skin cancer	0.00025	0.000757	CcSEcCtD
Nefazodone—Headache—Temozolomide—skin cancer	0.000249	0.000753	CcSEcCtD
Nefazodone—Hypotension—Docetaxel—skin cancer	0.000247	0.000747	CcSEcCtD
Nefazodone—Dizziness—Fluorouracil—skin cancer	0.000242	0.000732	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000241	0.000728	CcSEcCtD
Nefazodone—SLC6A4—female reproductive system—skin cancer	0.000239	0.0243	CbGeAlD
Nefazodone—Insomnia—Docetaxel—skin cancer	0.000239	0.000723	CcSEcCtD
Nefazodone—Paraesthesia—Docetaxel—skin cancer	0.000237	0.000718	CcSEcCtD
Nefazodone—Nausea—Temozolomide—skin cancer	0.000236	0.000714	CcSEcCtD
Nefazodone—Dyspnoea—Docetaxel—skin cancer	0.000236	0.000713	CcSEcCtD
Nefazodone—Somnolence—Docetaxel—skin cancer	0.000235	0.000711	CcSEcCtD
Nefazodone—Vomiting—Fluorouracil—skin cancer	0.000233	0.000704	CcSEcCtD
Nefazodone—Dyspepsia—Docetaxel—skin cancer	0.000233	0.000704	CcSEcCtD
Nefazodone—Rash—Fluorouracil—skin cancer	0.000231	0.000698	CcSEcCtD
Nefazodone—Dermatitis—Fluorouracil—skin cancer	0.000231	0.000698	CcSEcCtD
Nefazodone—Decreased appetite—Docetaxel—skin cancer	0.00023	0.000695	CcSEcCtD
Nefazodone—Headache—Fluorouracil—skin cancer	0.000229	0.000694	CcSEcCtD
Nefazodone—ABCB1—blood vessel—skin cancer	0.000229	0.0233	CbGeAlD
Nefazodone—Pain—Docetaxel—skin cancer	0.000226	0.000683	CcSEcCtD
Nefazodone—Constipation—Docetaxel—skin cancer	0.000226	0.000683	CcSEcCtD
Nefazodone—SLC6A3—head—skin cancer	0.000218	0.0221	CbGeAlD
Nefazodone—Feeling abnormal—Docetaxel—skin cancer	0.000218	0.000659	CcSEcCtD
Nefazodone—Nausea—Fluorouracil—skin cancer	0.000218	0.000658	CcSEcCtD
Nefazodone—Gastrointestinal pain—Docetaxel—skin cancer	0.000216	0.000654	CcSEcCtD
Nefazodone—ADRA2A—connective tissue—skin cancer	0.000211	0.0214	CbGeAlD
Nefazodone—HTR2C—head—skin cancer	0.000211	0.0214	CbGeAlD
Nefazodone—SLC6A2—female reproductive system—skin cancer	0.000211	0.0214	CbGeAlD
Nefazodone—Body temperature increased—Docetaxel—skin cancer	0.000209	0.000632	CcSEcCtD
Nefazodone—Abdominal pain—Docetaxel—skin cancer	0.000209	0.000632	CcSEcCtD
Nefazodone—ADRA1A—lymphoid tissue—skin cancer	0.000203	0.0206	CbGeAlD
Nefazodone—SLC6A4—head—skin cancer	0.0002	0.0203	CbGeAlD
Nefazodone—Hypersensitivity—Docetaxel—skin cancer	0.000195	0.000589	CcSEcCtD
Nefazodone—Asthenia—Docetaxel—skin cancer	0.00019	0.000573	CcSEcCtD
Nefazodone—Pruritus—Docetaxel—skin cancer	0.000187	0.000565	CcSEcCtD
Nefazodone—Diarrhoea—Docetaxel—skin cancer	0.000181	0.000547	CcSEcCtD
Nefazodone—HTR2A—connective tissue—skin cancer	0.000179	0.0182	CbGeAlD
Nefazodone—HTR1A—head—skin cancer	0.000177	0.018	CbGeAlD
Nefazodone—SLC6A2—head—skin cancer	0.000176	0.0179	CbGeAlD
Nefazodone—Dizziness—Docetaxel—skin cancer	0.000175	0.000529	CcSEcCtD
Nefazodone—ADRA2A—mammalian vulva—skin cancer	0.000174	0.0176	CbGeAlD
Nefazodone—HTR2A—epithelium—skin cancer	0.00017	0.0173	CbGeAlD
Nefazodone—Vomiting—Docetaxel—skin cancer	0.000168	0.000508	CcSEcCtD
Nefazodone—Rash—Docetaxel—skin cancer	0.000167	0.000504	CcSEcCtD
Nefazodone—Dermatitis—Docetaxel—skin cancer	0.000167	0.000503	CcSEcCtD
Nefazodone—Headache—Docetaxel—skin cancer	0.000166	0.000501	CcSEcCtD
Nefazodone—ADRA1A—head—skin cancer	0.000164	0.0166	CbGeAlD
Nefazodone—Nausea—Docetaxel—skin cancer	0.000157	0.000475	CcSEcCtD
Nefazodone—ADRA2A—female reproductive system—skin cancer	0.000149	0.0151	CbGeAlD
Nefazodone—HTR2A—female reproductive system—skin cancer	0.000127	0.0128	CbGeAlD
Nefazodone—ADRA2A—head—skin cancer	0.000124	0.0126	CbGeAlD
Nefazodone—SLC6A2—lymph node—skin cancer	0.000123	0.0125	CbGeAlD
Nefazodone—CYP3A4—female reproductive system—skin cancer	0.000117	0.0119	CbGeAlD
Nefazodone—CYP2D6—female reproductive system—skin cancer	0.000115	0.0117	CbGeAlD
Nefazodone—ABCB1—epithelium—skin cancer	0.000112	0.0113	CbGeAlD
Nefazodone—HTR2A—head—skin cancer	0.000106	0.0107	CbGeAlD
Nefazodone—ABCB1—mammalian vulva—skin cancer	9.69e-05	0.00983	CbGeAlD
Nefazodone—CYP2D6—head—skin cancer	9.63e-05	0.00978	CbGeAlD
Nefazodone—ADRA2A—lymph node—skin cancer	8.71e-05	0.00884	CbGeAlD
Nefazodone—ABCB1—lymphoid tissue—skin cancer	8.6e-05	0.00873	CbGeAlD
Nefazodone—ABCB1—female reproductive system—skin cancer	8.29e-05	0.00842	CbGeAlD
Nefazodone—ABCB1—head—skin cancer	6.93e-05	0.00703	CbGeAlD
Nefazodone—ABCB1—lymph node—skin cancer	4.85e-05	0.00492	CbGeAlD
